Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen Failure
- 20 September 2005
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (27), 6556-6560
- https://doi.org/10.1200/jco.2005.20.966
Abstract
Purpose For men receiving androgen-suppression therapy (AST) for a rising postoperative or postradiation prostate-specific antigen (PSA), we evaluated whether a PSA nadir of more than 0.2 ng/mL was...Keywords
This publication has 15 references indexed in Scilit:
- THE NATURAL HISTORY OF ANDROGEN INDEPENDENT PROSTATE CANCERJournal of Urology, 2004
- 10-Year Outcome for Men With Localized Prostate Cancer Treated With External Radiation Therapy:: Results of a Cohort StudyJournal of Urology, 2004
- Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation TherapyJNCI Journal of the National Cancer Institute, 2003
- Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate CancerJournal of Urology, 2003
- Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate CancerJournal of Urology, 2002
- ProstatePublished by Springer Nature ,2002
- Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-eraUrologic Oncology: Seminars and Original Investigations, 2001
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- Consensus statement: Guidelines for PSA following radiation therapy1International Journal of Radiation Oncology*Biology*Physics, 1997
- The capsure database: a methodology for clinical practice and research in prostate cancerUrology, 1996